+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Premenstrual Syndrome Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 141 Pages
  • November 2023
  • Region: Global
  • IMARC Group
  • ID: 5911999

Quick Summary:

In the dynamic landscape of the premenstrual syndrome treatment market, staying ahead means recognizing and harnessing the transformative shifts influenced by heightened awareness, innovative therapeutics, and evolving consumer needs. As senior business executives chart strategic courses, access to informed insights is essential for making investment decisions aligned with future growth trajectories.

This comprehensive market research report offers a deep dive into the rapidly expanding premenstrual syndrome treatment domain, with a focus on the novel therapeutic solutions that are reshaping patient care. It unpacks the trends fueling the sector's growth: an uptick in PMS and PMDD awareness, cutting-edge drug developments with fewer side effects, and the integration of technology in monitoring and managing symptoms. With segments ranging from drug types to distribution channels, this report illuminates the avenues poised for advancement, backed by robust data and analysis.

The global premenstrual syndrome treatment market size reached US$ 1.35 Billion in 2022. Looking forward, the market is expected to reach US$ 1.68 Billion by 2028, exhibiting a growth rate (CAGR) of 3.79% during 2022-2028.

Premenstrual syndrome (PMS) treatment refers to the therapeutic processes utilized for minimizing emotional, physical and psychological symptoms, such as bloating, breast tenderness, body pain, fatigue, mood fluctuations and anxiety, in women. PMS is commonly observed at the end of the luteal phase and dissipates with menstruation or shortly after. The treatment involves the use of antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, ovarian suppression agents and hormonal contraceptives. These drugs are usually available over the counter (OTC) or are prescribed by a doctor. Novel PMS treatment drugs, such as topical gels, creams, capsules and suppositories, are manufactured using cannabidiol extracts for the management of mood imbalances, minimizing uterine cramps and facilitating muscle relaxation.

Premenstrual Syndrome Treatment Market Trends

The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the female working population. Moreover, rising awareness among the masses regarding available treatment alternatives for PMS and other related disorders is providing a thrust to the market growth. Pharmaceutical manufacturers are launching medications that have minimal side effects and aid in maintaining the appropriate pH balance in the body. Additionally, the widespread adoption of nutritional supplements manufactured using plant-based sources to provide relief from PMS is acting as another growth-inducing factor. These supplements contain the recommended amount of nutrients, such as calcium, magnesium, potassium and proteins, that aid in reducing fatigue and easing anxiety and depression. Healthcare organizations are also developing smartphone applications that periodically record physiological and emotional changes occurring in the body and send notification alerts as medication reminders. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global premenstrual syndrome treatment market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on drug type, type and distribution channel.

Breakup by Drug Type:

  • Analgesics
  • Antidepressants
  • Oral Contraceptives and Ovarian Suppression Agents

Breakup by Type:

  • Prescription
  • Over-the-Counter

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

Key Questions Answered in This Report

1. What was the size of the global premenstrual syndrome treatment market in 2022?
2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2023-2028?
3. What are the key factors driving the global premenstrual syndrome treatment market?
4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
8. What are the key regions in the global premenstrual syndrome treatment market?
9. Who are the key players/companies in the global premenstrual syndrome treatment market?
Frequently Asked Questions about the Global Premenstrual Syndrome Treatment Market

What is the estimated value of the Global Premenstrual Syndrome Treatment Market?

The Global Premenstrual Syndrome Treatment Market was estimated to be valued at $1.35 Billion in 2022.

What is the growth rate of the Global Premenstrual Syndrome Treatment Market?

The growth rate of the Global Premenstrual Syndrome Treatment Market is 3.8%, with an estimated value of $1.68 Billion by 2028.

What is the forecasted size of the Global Premenstrual Syndrome Treatment Market?

The Global Premenstrual Syndrome Treatment Market is estimated to be worth $1.68 Billion by 2028.

Who are the key companies in the Global Premenstrual Syndrome Treatment Market?

Key companies in the Global Premenstrual Syndrome Treatment Market include Abbott Laboratories, Biomérieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd and Thermo Fisher Scientific Inc.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Premenstrual Syndrome Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Analgesics
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Antidepressants
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Oral Contraceptives and Ovarian Suppression Agents
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Type
7.1 Prescription
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Over-the-Counter
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 BASF SE
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Dr. Reddy’s Laboratories Ltd
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Eli Lilly and Company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 GlaxoSmithKline Plc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 H. Lundbeck A/S
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 SHIONOGI & Co. Ltd.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis

Companies Mentioned

  • AbbVie Inc.
  • BASF SE
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • SHIONOGI & Co. Ltd.

Methodology

Loading
LOADING...